← ANALYST RATINGS · TIPRANKS
Neumora Therapeutics, Inc. (NMRA): analyst forecast and price target
Analyst consensus
Strong Buy5 Buy0 Hold0 Sell
Ratings of 5 analysts in the last 3 months · top analysts only12-month forecast
Based on 5 price targets given in the last 3 months, the average target is $5.25, the highest $7.00, the lowest $4.00. The average is +1,009.9% from the last price of $0.47.
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $0.42 → $0.46+9.0% | Hold | −2.5% | Reiterated | 17.10.26on TipRanks 08:06 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $0.42 → $0.45+7.4% | Hold | −4.4% | Reiterated | 17.10.26on TipRanks 08:06 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $0.41 → $0.46+13.0% | Hold | −2.5% | Reiterated | 17.10.26on TipRanks 08:06 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $0.41 → $0.43+3.4% | Sell | −9.5% | Downgrade | 17.10.26on TipRanks 08:06 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $0.41 → $0.45+9.2% | Hold | −4.4% | Reiterated | 17.10.26on TipRanks 08:06 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $0.41 → $0.45+8.5% | Sell | −5.5% | Downgrade | 17.10.26on TipRanks 08:06 | — | |
| Douglas Tsao★★★★★★★★★★#207 · hits 56% · avg +24.3% | H.C. Wainwright | $7.00 | Buy | +1,379.9% | Reiterated | 24.08.26on TipRanks 08:06 | −6.1%next day −2.0% · 5 days −13.3% | ↗ |
| Graig Suvannavejh★★★★★★★★★★#381 · hits 48% · avg +21.6% | Mizuho Securities | $4.00 | Buy | +745.7% | Reiterated | 17.08.26on TipRanks 06:32 | −4.5%next day +8.6% · 5 days +1.5% | ↗ |
| Brian Abrahams★★★★★★★★★★#481 · hits 57% · avg +15.1% | RBC Capital | $5.00 | Buy | +957.1% | Reiterated | 14.08.26on TipRanks Aug 17 21:45 | −7.3%next day −4.5% · 5 days +3.2% | ↗ |
| Ami Fadia★★★★★★★★★★#73 · hits 59% · avg +36.1% | Needham | $5.00 | Buy | +957.1% | Reiterated | 14.08.26on TipRanks 12:30 | −7.3%next day −4.5% · 5 days +3.2% | ↗ |
| Myles Minter★★★★★★★★★★#92 · hits 61% · avg +34.9% | William Blair | — | Buy | — | Reiterated | 14.08.26on TipRanks 12:15 | −7.3%next day −4.5% · 5 days +3.2% | ↗ |
| Tessa Romero★★★★★★★★★★#805 · hits 57% · avg +21.7% | J.P. Morgan | — | Sell | — | Reiterated | 26.05.26on TipRanks May 27 07:16 | −1.2%next day +1.1% · 5 days −6.1% | ↗ |
| Paul Matteis★★★★★★★★★★#473 · hits 53% · avg +17.6% | Stifel Nicolaus | $3.00 | Hold | +534.2% | Reiterated | 12.05.26on TipRanks 07:20 | +1.8%next day −6.9% · 5 days −11.5% | ↗ |
| Yatin Suneja★★★★★★★★★★#120 · hits 57% · avg +33.0% | Guggenheim | $14.00 | Buy | +2,859.8% | Reiterated | 07.05.26on TipRanks May 8 07:30 | −16.4%next day −6.5% · 5 days −0.7% | ↗ |
| Marc Goodman★★★★★★★★★★#365 · hits 56% · avg +19.2% | Leerink Partners | $8.00 | Buy | +1,591.3% | Initiated | 11.01.26on TipRanks Jan 12 07:32 | −0.2%next day −3.4% · 5 days −13.2% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Neumora Therapeutics, Inc.
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $5.25 at a price of $0.60 (+780.9%); now: $5.25 at $0.47 (+1,009.9%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 14 | 15 | 15 | 14 | 8 | 5 |
| Buy | 2 | 2 | 3 | 3 | 2 | 1 |
| Hold | 2 | 2 | 1 | 0 | 0 | 0 |
| Sell | 1 | 1 | 1 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 04.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.20 (from $-0.22 to $-0.17). Last quarter: $-0.23.
Best top-analyst consensus in the sector · Healthcare
About Neumora Therapeutics, Inc.
- CEO: Josh Pinto
- Employees: 63
- 490 Arsenal Way, Watertown, MA, 02472, US
- www.neumoratx.com
Neumora Therapeutics, Inc. is a specialized biopharmaceutical company progressing through clinical trials, dedicated to advancing therapies for a range of neurological, psychiatric, and neurodegenerative conditions. Its most advanced candidate, navacaprant (also known as NMRA-140), is a novel, once-daily oral kappa opioid receptor antagonist currently undergoing Phase 3 clinical trials for the management of major depressive disorder. Additionally, NMRA-511 is in Phase 1 studies, targeting agitation experienced by individuals with Alzheimer's-related dementia. Another compound, NMRA-266, is also in Phase 1 clinical development, aimed at addressing schizophrenia and other related neuropsychiatric conditions. Beyond its clinical programs, Neumora maintains a preclinical pipeline featuring several promising candidates: NMRA-NMDA for schizophrenia, NMRA-CK1d (a CK1d inhibitor initiative) for amyotrophic lateral sclerosis (ALS), NMRA-NLRP3 for specific neurodegenerative ailments, and NMRA-GCase for Parkinson's disease. Tracing its origins to a 2019 incorporation, the company, initially known as RBNC Therapeutics, Inc., adopted its current name, Neumora Therapeutics, Inc., in October 2021. Its corporate headquarters are situated in Watertown, Massachusetts.
Data from the stock’s TipRanks forecast page, read 146 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗